New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
10:33 EDTWSM, IRDM, LGND, SEAS, HSOLHigh option volume stocks: IRDM HSOL LGND WSM SEAS
News For IRDM;HSOL;LGND;WSM;SEAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
10:01 EDTSEASOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AT&T (T) initiated with a Buy at DA Davidson... Abaxis (ABAX) initiated with an Underperform at Credit Suisse... Aratana Therapeutics (PETX) initiated with an Outperform at Credit Suisse... Care.com (CRCM) initiated with an Equal Weight at Morgan Stanley... GCP Applied Technologies (GCP) initiated with a Buy at Jefferies... Heritage-Crystal Clean (HCCI) initiated with a Buy at Roth Capital... IDEXX (IDXX) initiated with an Outperform at Credit Suisse... Nexvet Biopharma (NVET) initiated with an Outperform at Credit Suisse... PetMed Express (PETS) initiated with an Underperform at Credit Suisse... Phibro Animal Health (PAHC) initiated with an Outperform at Credit Suisse... Pure Storage (PSTG) initiated with a Perform at Oppenheimer... SeaWorld (SEAS) initiated with a Neutral at Janney Capital... Seattle Genetics (SGEN) initiated with an Overweight at Barclays... VCA Inc. (WOOF) initiated with an Outperform at Credit Suisse... Verizon (VZ) initiated with a Neutral at DA Davidson... Zoetis (ZTS) initiated with an Outperform at Credit Suisse.
08:00 EDTSEASSeaWorld initiated with a Neutral at Janney Capital
Subscribe for More Information
February 3, 2016
11:37 EDTWSMOptions with increasing put volume; PSX CDNS DF WDR MELI MAS NOV WSM DB
Subscribe for More Information
11:00 EDTSEASBarrow, Hanley reports 10.30% passive stake in SeaWorld
Subscribe for More Information
February 2, 2016
09:01 EDTLGNDLigand enters into OmniAb platform license pact with Tizona
Ligand Pharmaceuticals announced it has entered into a worldwide license agreement with Tizona Therapeutics, Inc. Under the license, Tizona will use the OmniRat, OmniMouse and OmniFlic platforms to generate fully human mono- and bispecific antibodies. Ligand will be eligible to receive annual platform access payments as well as patent filing fees, clinical milestone payments and royalties for each successful OmniAb antibody. Tizona will be responsible for all costs related to the program.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use